What is the impact of changes in hepatic drug enzyme activity on drug effects?
Hepatic drug-metabolizing enzymes, also known as the hepatic microsomal mixed-function enzyme system, are key enzymes responsible for the biotransformation of most drugs in the body. Changes in the activity of these enzymes—either increased or decreased—directly affect the rate of drug metabolism and bioavailability, thereby influencing the pharmacological effects of drugs. The analysis is as follows:

When hepatic enzyme activity increases, the rate of drug metabolism accelerates, shortening the drug's residence time in the body and correspondingly reducing its pharmacological effect. During long-term medication, enhanced enzyme activity may lead to tolerance, meaning higher drug doses are required to achieve the original therapeutic effect.
When hepatic enzyme activity decreases, drug metabolism slows down. As a result, the effective drug concentration in the body increases, enhancing therapeutic effects. However, this may also increase the risk of adverse effects. With prolonged use, reduced enzyme activity can lead to drug accumulation, potentially causing adverse reactions or toxicity.
When designing drug regimens, physicians should fully consider the patient’s liver function status and potential changes in hepatic enzyme activity to ensure both efficacy and safety. Additionally, for patients requiring hepatic enzyme inhibitors or inducers, close monitoring of blood drug concentrations and adverse reactions is essential, with timely adjustments to the treatment plan as needed.